Buchumschlag

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Amarenco, Pierre (VerfasserIn) , Bogousslavsky, Julien (VerfasserIn) , Callahan, Alfred S. (VerfasserIn) , Goldstein, Larry (VerfasserIn) , Hennerici, Michael G. (VerfasserIn) , Sillsen, Henrik (VerfasserIn) , Welch, Michael A. (VerfasserIn) , Zivin, Justin A. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 19, 2003
In: Cerebrovascular diseases
Year: 2003, Jahrgang: 16, Heft: 4, Pages: 389-395
ISSN:1421-9786
DOI:10.1159/000072562
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000072562
Volltext
Verfasserangaben:the SPARCL Investigators
Beschreibung
Zusammenfassung:Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.
Beschreibung:Prepared by the SPARCL Publications Committee for the SPARCL Investigators: Pierre Amarenco, Julien Bogousslavsky, Alfred S. Callahan, Larry Goldstein, Michael Hennerici, Henrik Sillsen, Michael A. Welch, Justin Zivin
Gesehen am 01.06.2022
Beschreibung:Online Resource
ISSN:1421-9786
DOI:10.1159/000072562

Ähnliche Einträge